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Excessive deposition of fat in the liver (hepatic steatosis) is frequently accompanied by hepatic insulin resis-
tance.Whether this correlation is due to a causal relationship between the conditions has been the subject of
considerable debate, and the literature abounds with conflicting data and theories. Here we provide
a perspective by defining the problem and its challenges, analyzing the possible causative relationships,
and drawing some conclusions.The Problem
With more obesity in the developed world, the prevalence of
hepatic steatosis, or fatty liver, has increased. An estimated
1/3 of the population in the United States is obese (BMI > 30)
and 40% have type 2 diabetes or prediabetes (http://www.
cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf). In response to
overtaxed adipose tissues, human livers attempt to compensate
as a storage depot for triglycerides (TGs). This has resulted in an
epidemic of nonalcoholic fatty liver disease (NAFLD), with a prev-
alence of up to 30% in the United States (Lazo and Clark, 2008).
Unfortunately, excessive fat in the liver is associated with organ
pathology, including nonalcoholic steatohepatitis (NASH) and
cirrhosis, which can lead to liver failure.
In humans, hepatic steatosis is often accompanied by hepatic
insulin resistance (IR). This raises an important question: Does
hepatic steatosis cause hepatic IR? Or, is the correlation
between these two phenomena due to a common underlying
molecular pathophysiology? Alternatively, does IR cause
hepatic steatosis?
In this perspective, we outline some of the challenges to
solving this problem, analyze issues of causality, and draw
some conclusions.
Some Background
Hepatic steatosis, the excessive accumulation of lipids in the
liver, usually refers to the build-up of neutral lipids, such as
TGs or cholesterol esters, in lipid droplets of hepatocytes. The
bulk of the evidence suggests that inert lipids, such as TG, con-
tained within lipid droplets are not toxic. Besides neutral lipids,
other lipids, including diacylglycerols (DAGs), ceramides, fatty
acids, and their metabolites, often accumulate. These lipids
are potentially bioactive and could therefore interfere with hepa-
tocyte function and particularly with the ability of hepatocytes to
respond to changes in insulin levels.
The failure of hepatocytes to respond to insulin contributes
to the development of glucose intolerance and, ultimately, to570 Cell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc.fasting hyperglycemia and type 2 diabetes. In the liver, insulin
normally acts through cell-surface receptors to suppress glyco-
genolysis and gluconeogenesis and to promote glycogen
synthesis and lipogenesis. Hepatic IR usually refers to the
impaired ability of insulin to suppress hepatic glucose produc-
tion. Failure of the insulin system under such circumstances is
usually not due to reduced levels of the hormone, since in obesity
and diabetes-associated systemic IR, circulating insulin levels
are often elevated. Instead, insulin signaling is impaired in
insulin-resistant hepatocytes. More precisely, the insulin-stimu-
lated signal transduction pathway that suppresses hepatic
glucose production does not function normally. This signaling
pathway includes the insulin receptor, IRS proteins, PI 3-kinase,
Akt/protein kinase B (PKB), FoxO1, and presumably other down-
stream mediators (Haas and Biddinger, 2009; Leavens and
Birnbaum, 2011). In steatosis-associated IR, defects in this
signaling pathway are thought to occur at specific signaling
steps, manifesting as defects in FoxO1 phosphorylation and
increases in gluconeogenesis (Gross et al., 2009).
While these aspects of insulin’s action on the hepatic gluco-
neogenic pathway are impaired, insulin’s signaling to hepatic
SREBP-1c and the lipogenic pathway (e.g., via atypical PKCs
and possibly other PKCs) are thought to remain intact or to
even be hyperstimulated (Farese and Sajan, 2010; Shimomura
et al., 2000), thus promoting hepatic lipid synthesis and steato-
sis. Specific resistance to insulin’s effects on suppressing
hepatic glucose production, but not lipogenesis, is referred to
as selective IR (Brown and Goldstein, 2008). Thus, in insulin-
resistant states of obesity and type 2 diabetes, hepatic lipid
production is increased paradoxically in concert with increased
hepatic glucose production.
Challenges to Solving the Problem
Addressing the relationship between hepatic steatosis and IR
presents considerable challenges. First, our view of insulin
signaling in the liver is likely incomplete. A recent study of the
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hundreds of changes in phosphorylation in cellular proteins,
many of which had not been described as parts of the insulin-
signaling network (Monetti et al., 2011b). Thus, most studies
that measure one or a few changes in the canonical pathway
of insulin signaling likely ignore other important effects of the
hormone, some of which may affect the development of IR.
Second, it is impossible to study the accumulation of a specific
lipid in isolation. Any change in a lipid metabolic pathway
induced by an experimental intervention will almost assuredly
result in compensatory changes in other pathways affecting
discrete lipid pools. Moreover, analyses of lipids in livers are
most often incomplete. Only some lipids are measured,
frequently by different assays in different laboratories, and
usually only general classes are measured, without differentia-
tion of individual lipid species or their concentration within
specific subcellular compartments. Third, the liver is influenced
by multiple hormonal and neural inputs and is itself a complex
tissue with several cell types, including hepatocytes, macro-
phage-related reticulo-endothelial cells, and stellate cells.
Studies of cultured liver cells reduce the complexity of the
problem, but most hepatocytes in culture lose insulin respon-
siveness, so fail to model the in vivo situation. Finally, the assess-
ment of hepatic IR is not standardized. Many different assays are
employed, including measurements of hepatic insulin signaling
factors (by either phosphorylation states, enzyme activities, or
enzyme amounts within membrane compartments), systemic
measurements of glucose metabolism, or hyperinsulinemic-
euglycemic insulin clamp studies. The latter method—consid-
ered the gold standard test in humans—presents significant
technical and standardization challenges in mice (McGuinness
et al., 2009). A lack of standardized criteria for measuring hepatic
IR contributes to confusion in the literature with regard to the
role of steatosis in its development.
Does Hepatic Steatosis Cause Insulin Resistance?
Many studies report a correlation between development of
hepatic IR and accumulation of tissue lipids (e.g., TG, DAG,
ceramides, or fatty acyl CoAs). But does the accumulation of
specific lipids cause hepatic IR, or are both phenomena conse-
quences of another condition? Problems of causality can be
considered by addressing questions of sufficiency and neces-
sity. Establishing causality is difficult: although consistent ex-
perimental results support or establish a theory, even a single
contradictory result can refute it.
Is there a specific lipid, which upon accumulating to exces-
sive levels in the liver, that invariably (‘‘if and only if’’) causes
hepatic IR? The available data indicate not. Steatosis normally
refers to the accumulation of neutral lipids, such as TG or
cholesterol esters. Numerous murine models accumulate TGs
in the liver without accompanying IR. These include models
with altered fatty acid synthesis (Chakravarthy et al., 2005),
storage (Monetti et al., 2007), mobilization (Brown et al.,
2010; Hoy et al., 2011; Minehira et al., 2008; Wu et al., 2011),
and oxidation (Monsenego et al., 2011). Also, numerous studies
of humans with mutations or genetic variations in genes that
cause or contribute to hepatic TG accumulation, such as
ATGL, CGI58, or PNPLA3, are not associated with IR (Cohen
et al., 2011; Hooper et al., 2011). Thus, since TG accumulationis not invariably associated with hepatic IR, it cannot be consid-
ered as sufficient.
Numerous other lipids, including DAGs, ceramides, and fatty
acyl CoAs, have been associated with hepatic IR (Nagle et al.,
2009; Samuel et al., 2010; Summers, 2010). Excessive accumu-
lation of these molecules might interfere with insulin signaling
to regulate glucose production. In particular, DAGs activate
conventional (classical) and novel protein kinase Cs, and
ceramides activate atypical protein kinase Cs and c-Jun
N-terminal kinases (JNK). Both classes of kinases might then
interfere with insulin signaling by phosphorylation of key sig-
naling molecules, such as the insulin receptor or IRS proteins
(Morino et al., 2006; Vallerie and Hotamisligil, 2010). In many
instances, the accumulation of these lipids in the liver is associ-
ated with hepatic IR (Cohen et al., 2011; Nagle et al., 2009;
Samuel et al., 2010; Summers, 2010). Thus, it is reasonable to
implicate these molecules as sufficient for causing or promoting
hepatic IR.
DAGhas been suggested as a unifyingmediator (Samuel et al.,
2010), although its role in causing hepatic IR has recently been
debated (Jornayvaz et al., 2011; Monetti et al., 2011a; Monetti
et al., 2007). Several studies inmurinemodels and humans found
normal hepatic insulin sensitivity in the setting of steatosis with
elevated DAG levels (Brown et al., 2010; Minehira et al., 2008;
Monetti et al., 2007; Voshol et al., 2003), refuting the hypothesis
that liver DAG levels per se are causative. This does not exclude,
however, the possibility that a particular DAG species is suffi-
cient for driving hepatic IR in somemodels. DAG refers to a class
of lipid molecules, and DAG species differ in the position and
types of fatty acid side chains. Evidence suggests that only
specific DAG species (i.e., sn-1,2-diacylglycerols) are potent
activators of PKC enzymes (Boni and Rando, 1985). Moreover,
measurement of total organ DAG levels, the method employed
by most groups to date, may obscure elevations of DAG levels
within a specific subcellular compartment that could activate
PKC (e.g., at the plasma membrane). Such events may be
required for DAG to serve as a mediator of insulin resistance.
At present, there are few data addressing DAG species or DAG
localization in models of hepatic steatosis associated with
hepatic IR, although one recent study correlated DAG content
in lipid droplets, as well as total liver DAG content, with plasma
indices of IR (Kumashiro et al., 2011). This study was correlative
in nature, however, and did not directly address causation. More
studies are needed on both DAG species and compartmentali-
zation with respect to sufficiency for causing hepatic IR. Similar
arguments can be made for other lipids, including fatty acyl-
CoAs and ceramides, which in excess are sometimes, but not
always, associated with hepatic IR (Summers, 2010) and do
not fulfill strict criteria for sufficiency arguments.
The available data indicate that most lipids fail the criteria of
sufficiency for causing hepatic IR. What about their necessity
for hepatic IR? The data show that hepatic IR can arise as a result
of conditions other than lipid accumulation in the liver. For
example, a murine model with hepatocyte-specific deletion of
the insulin receptor exhibits marked IR but lacks hepatic steato-
sis (Biddinger et al., 2008). Moreover, humans with mutations in
the insulin receptor are insulin resistant, but also lack hepatic
steatosis (Semple et al., 2009). Thus, steatosis is not a strict
requirement for developing hepatic IR.Cell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc. 571
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lipid accumulation and IR is that these lipids are not causative for
hepatic IR, but instead might be markers for an underlying and
causative insult. Numerous models have been proposed for
causes of hepatic IR that are conceptually independent of lipid
accumulation. Most prominently, ER stress and inflammation in
the liver are hypothesized to lead to IR (Gregor and Hotamisligil,
2011; Hummasti and Hotamisligil, 2010). However, in many
cases, these conditions are also associated with lipid accumula-
tion, which confounds interpretations. Saturated fatty acids,
such as palmitate, can drive the production of DAGs or ceram-
ides and trigger processes, such as ER stress and inflammation,
that alter cellular signaling. Small nucleolar RNAs were recently
identified as possible mediators of palmitate-induced cellular
toxicity (Michel et al., 2011), and their role in hepatic IR should
be examined.
Does Hepatic Insulin Resistance Cause Hepatic
Steatosis?
IR is often accompanied by increased circulating insulin levels. In
turn, insulin can drive hepatic lipid synthesis in the liver through
the activation of one or more of the several insulin-sensitive
signaling factors that increase activity and expression of
SREBP-1c and an array of lipogenic enzymes. Although inactiva-
tion of the insulin receptor in the liver does not cause steatosis
(Biddinger et al., 2008), siRNA-mediated suppression of the
downstream IRS proteins in the liver results in hepatic IR, hyper-
insulinemia, and steatosis (Taniguchi et al., 2005). Thus, in this
case, specific defects of insulin signaling in the liver are sufficient
to cause steatosis. Additionally, it is widely accepted that
systemic IR results in hyperinsulinemia and liver steatosis
(Cohen et al., 2011). Stated differently, hepatic steatosis can
hypothetically be the result or cause of hepatic IR. This bidirec-
tionality illustrates the difficult nature of establishing causal rela-
tionships for these conditions.
Conclusions
To date, no specific lipid has been shown to be both necessary
and sufficient to cause hepatic IR. The available data indicate
that the accumulation of neutral TGs is not causative. It also
seems clear that, at the whole tissue level, excessive bioactive
lipids, such as DAGs or ceramides, do not fulfill a strict causative
relationship, as they are not always sufficient. Whether specific
species of such bioactive lipids within specific compartments
of hepatocytes can cause hepatic IR remains an active area of
investigation.
Another possibility is that different routes lead to hepatic IR,
and excess bioactive lipids act as contributing factors. Other
processes, such as ER stress or inflammation, also may be
sufficient as contributors in some circumstances. In this manner,
the accumulation of different lipids, such as DAGs or ceramides,
may act as contributing factors, which when combined with
other contributing factors, result in a cellular state that is suffi-
cient, but not required, to cause hepatic IR.
The likelihood of solving the problem of causation will be
greater if measurements are refined. This applies to hepatic IR
and to steatosis. Hepatic IR likely refers to a heterogeneous
set of conditions that manifest in impaired inhibition of glycogen-
olysis and gluconeogenesis, and it would be useful to define572 Cell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc.uniform criteria for what constitutes hepatic IR. More compre-
hensive lipid analyses, including measurements of individual
lipid species, and defining types of cells and subcellular
compartments in which changes in levels of specific lipids occur
may identify new candidate lipids that are causally related to IR.
Additionally, the application of unbiased, systems-type screens
(e.g., genetics, proteomics, lipidomics, metabolomics) to the
problem may yield new theories of causation.ACKNOWLEDGMENTS
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